breakthrough disease

breakthrough disease

(brāk′throo″)
Any disease that occurs in spite of adequate vaccination to prevent it, (e.g., “breakthrough varicella” or “breakthrough influenza”).
References in periodicals archive ?
Although penicillin prophylaxis and pneumococcal polysaccharide vaccine have decreased the rate of invasive pneumococcal disease (IPD) in this high-risk population, breakthrough disease still occurs--most commonly among children younger than 3 years--and IPD continues to be a leading cause of death in children with SCD, the researchers explained.
The bottom line was you were very much (more) likely to get breakthrough disease the longer you were (past) getting the first vaccine," Mascola said.
Four published studies have also documented an increase in breakthrough disease with time.
On December 11, MDCH and Oakland County public health epidemiologists, with the technical assistance of CDC, conducted a retrospective cohort study to describe the outbreak, determine varicella vaccine effectiveness (VE), and examine risk factors for breakthrough disease (i.
Chronix Biomedical to Launch Breakthrough Disease Detection and Monitoring Service for Clinical Researchers at ASCO
The study, called SURPASS, is expected to enroll 1,800 patients in 27 countries and provide direct comparative data of different treatment options for RRMS patients who experience breakthrough disease activity.
SURPASS is expected to enroll 1,800 patients in 27 countries and provide direct comparative data of different treatment options for RRMS patients who experience breakthrough disease activity.
McFarland said a health maintenance organization study found that inhaled steroids given 3 months prior to VZV vaccination were not associated with increased risk of breakthrough disease (Pediatrics 2003;112:e98-e113), but the study did find increased breakthrough disease after VZV vaccination when oral steroids were given in the 3 months prior.
Cox proportional hazards models were used to estimate the relative risks (RRs) for breakthrough disease between children receiving Var and other recommended childhood vaccines at different intervals, group-matched on year of birth, year and month of vaccination, and HMO membership.
SURPASS is a global, Phase IIIb, multicenter, randomized, rater-blinded, parallel-group, active-controlled trial designed to provide direct comparative data to inform patients and physicians of the relative benefits of different treatment options when faced with breakthrough disease activity.
Reports of outbreaks of mild cases of chickenpox among immunized children in child care centers led to studies showing that breakthrough cases of disease after vaccination occur in about 15% of children exposed to the wild-type virus, although breakthrough disease usually produces fewer than 50 lesions; is less severe; and, generally, is half as contagious as natural chickenpox.